Loading stock data…
RIGL
$29.40+0.50 (+1.73%)
Market ClosedLast close May 1
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rigel Pharmaceuticals, Inc. in the Healthcare sector is trading at $29.40. The stock is currently 44% below its 52-week high of $52.24, remaining 13.9% below its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why RIGL maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$29.40
Potential Upside
1370.3%
Whystock Fair Value$432.26
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Buy
Mean target$51.20+74.1%
Range$38.00 – $71.00
Fundamentals
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibito...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$563.09M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
1.56
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.27
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
24.99%
Volume
Today's trading volume
177,718
Recent News
Rigel Pharmaceuticals (RIGL) to Report Q1 Results: Wall Street Expects Earnings Growth
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Rigel Pharmaceuticals Stock?
Investors need to pay close attention to RIGL stock based on the movements in the options market lately.
Jim Cramer Blesses Rigel Pharmaceuticals as a Spec as “It’s Doing Better Than People Realize”
Jim Cramer reviewed Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) while breaking down 16 stocks for a market facing higher energy costs and economic uncertainty. When a caller asked about the stock during the lightning round, Cramer said: Okay, I think we, I have to tell you, I think that this company is real. It’s doing better than […]
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?
Madrigal (MDGL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
Today, March 16, 2026, investors weigh striking early colorectal cancer results against weak quarterly numbers and a finite cash runway.